Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16857693 | 1.00 | ALDH1A1 (0.40) | ALDH1A1KDM1AMAOBCFTRGOPC | |
| SCHEMBL1673336 | 1.00 | ALDH1A1 (0.40) | ALDH1A1KDM1AMAOBCFTRGOPC | |
| SCHEMBL17421924 | 0.75 | ALDH1A1 (0.36) | ALDH1A1KDM1AMAOBCFTRGOPC | |
| SCHEMBL8516623 | 0.73 | CFTR (0.50) | ALDH1A1KDM1AMAOBCFTRGOPC | |
| SCHEMBL27770531 | 0.70 | CFTR (0.35) | ALDH1A1CFTRGOPC | |
| SCHEMBL24613001 | 0.63 | KDM1A (0.33) | KDM1AMAOBCFTRGOPC | |
| Biphenyl SCHEMBL4002609 | 0.61 | ALDH1A1 (1.00) | ALDH1A1MAOACYP2B6 | |
| Biphenyl SCHEMBL2548048 | 0.61 | ALDH1A1 (1.00) | ALDH1A1MAOACYP2B6 | |
| Biphenyl SCHEMBL1358618 | 0.61 | ALDH1A1 (1.00) | ALDH1A1MAOACYP2B6 | |
| SCHEMBL29560186 | 0.61 | ALDH1A1 (1.00) | ALDH1A1MAOACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-20160039795-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-11 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092501-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | ALDH1A1 2195/4885KDM1A 443/4885MAOB 928/4885 |
| US-20160039795-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | ALDH1A1 2195/4885KDM1A 443/4885MAOB 928/4885 |
| US-20140065095-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | ALDH1A1 2195/4885KDM1A 443/4885MAOB 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.